Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD and tetratricopeptide repeats 1 (WDTC1) is a protein encoded by the WDTC1 gene in humans and is highly conserved across species. It acts as a suppressor of lipid accumulation and inhibits adipogenesis (the formation of fat cells), with loss or reduced function leading to increased triglyceride accumulation and susceptibility to obesity. WDTC1 is characterized by multiple WD40 repeats and tetratricopeptide repeat (TPR) domains, and functions primarily as a substrate receptor for the CUL4-DDB1 E3 ubiquitin ligase complex. It is involved in protein ubiquitination, chromatin modulation (including histone binding and histone H2AK119 monoubiquitylation), and negative regulation of fat accumulation and adipocyte gene expression. WDTC1 operates both in the cytosol and nucleus, forming complexes with components such as DDB1, CUL4A/4B, and ROC1. Its expression and functional integrity are required for the proper suppression of adipogenic differentiation, and perturbations are associated with increased fat mass in animal models and potential obesity risk in humans[1][2][3][4][5]. **Notes on druggability and target status:** - WDTC1 is not a classical therapeutic target such as a receptor, enzyme, transporter, or ion channel. It is best described as a regulator of cellular metabolism and chromatin state, with genetic evidence for its role in obesity. No drugs directly targeting WDTC1 are currently reported, nor is it considered a clinical therapeutic target as of this time[1][3][4]. **Relevant structure and functional notes:** - Multiple WD40 domains - Three tetratricopeptide repeat (TPR) domains - DDB1 binding elements (for CRL4 E3 ligase complex assembly) - Locations: Predominantly cytoplasmic, with nuclear and chromatin-associated fractions[1][2][6] **Common database identifiers:** - NCBI Gene: 23038 - HGNC: 29175 - UniProt: Q8N5D0 - Ensembl: ENSG00000142784[1][3] If structured information on drug interaction, biomarkers, or safety becomes available in the future, these fields should be updated accordingly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD and tetratricopeptide repeats 1 (WDTC1).